Pernix Therapeutics Holdings Inc is a specialty pharmaceutical company engaged in identifying, developing and commercializing differentiated products that address unmet medical needs. Its portfolio of approved products that address medical needs in several therapeutic areas, including Migraine, Treximet fixed dose combination product indicated for the treatment of acute migraine; Pain: Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate; and Insomnia, Silenor, the only non-narcotic, non-scheduled and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance.